215 related articles for article (PubMed ID: 28138837)
1. Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer's Disease.
Chase TN; Farlow MR; Clarence-Smith K
Neurotherapeutics; 2017 Apr; 14(2):405-416. PubMed ID: 28138837
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.
Doody RS; Corey-Bloom J; Zhang R; Li H; Ieni J; Schindler R
Drugs Aging; 2008; 25(2):163-74. PubMed ID: 18257603
[TBL] [Abstract][Full Text] [Related]
3. Donepezil for dementia due to Alzheimer's disease.
Birks JS; Harvey RJ
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD001190. PubMed ID: 29923184
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.
Farlow MR; Salloway S; Tariot PN; Yardley J; Moline ML; Wang Q; Brand-Schieber E; Zou H; Hsu T; Satlin A
Clin Ther; 2010 Jul; 32(7):1234-51. PubMed ID: 20678673
[TBL] [Abstract][Full Text] [Related]
5. The effects of donepezil in Alzheimer's disease - results from a multinational trial.
Burns A; Rossor M; Hecker J; Gauthier S; Petit H; Möller HJ; Rogers SL; Friedhoff LT
Dement Geriatr Cogn Disord; 1999; 10(3):237-44. PubMed ID: 10325453
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
7. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.
Rogers SL; Doody RS; Mohs RC; Friedhoff LT
Arch Intern Med; 1998 May; 158(9):1021-31. PubMed ID: 9588436
[TBL] [Abstract][Full Text] [Related]
8. Donepezil for dementia due to Alzheimer's disease.
Birks J; Harvey RJ
Cochrane Database Syst Rev; 2006 Jan; (1):CD001190. PubMed ID: 16437430
[TBL] [Abstract][Full Text] [Related]
9. Donepezil for mild and moderate Alzheimer's disease.
Birks J S; Melzer D
Cochrane Database Syst Rev; 2000; (2):CD001190. PubMed ID: 10796620
[TBL] [Abstract][Full Text] [Related]
10. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials.
Whitehead A; Perdomo C; Pratt RD; Birks J; Wilcock GK; Evans JG
Int J Geriatr Psychiatry; 2004 Jul; 19(7):624-33. PubMed ID: 15254918
[TBL] [Abstract][Full Text] [Related]
11. Donepezil for dementia due to Alzheimer's disease.
Birks JS; Harvey R
Cochrane Database Syst Rev; 2003; (3):CD001190. PubMed ID: 12917900
[TBL] [Abstract][Full Text] [Related]
12. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group.
Homma A; Takeda M; Imai Y; Udaka F; Hasegawa K; Kameyama M; Nishimura T
Dement Geriatr Cogn Disord; 2000; 11(6):299-313. PubMed ID: 11044775
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
[TBL] [Abstract][Full Text] [Related]
15. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease--pilot study.
Prasher VP; Huxley A; Haque MS;
Int J Geriatr Psychiatry; 2002 Mar; 17(3):270-8. PubMed ID: 11921156
[TBL] [Abstract][Full Text] [Related]
16. Donepezil for mild and moderate Alzheimer's disease.
Birks JS; Melzer D; Beppu H
Cochrane Database Syst Rev; 2000; (4):CD001190. PubMed ID: 11034704
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy.
Sakka P; Tsolaki M; Hort J; Hager K; Soininen H; López Pousa S; Li C; Schwam E
Curr Med Res Opin; 2007 Dec; 23(12):3153-65. PubMed ID: 17988434
[TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease.
Farlow M; Veloso F; Moline M; Yardley J; Brand-Schieber E; Bibbiani F; Zou H; Hsu T; Satlin A
BMC Neurol; 2011 May; 11():57. PubMed ID: 21612646
[TBL] [Abstract][Full Text] [Related]
19. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of multivitamin supplementation containing vitamins B6 and B12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer's disease: a 26-week, randomized, double-blind, placebo-controlled study in Taiwanese patients.
Sun Y; Lu CJ; Chien KL; Chen ST; Chen RC
Clin Ther; 2007 Oct; 29(10):2204-14. PubMed ID: 18042476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
